Key facts
- Kesmalea Therapeutics’s last known valuation is $39.0M.
- It has raised $37.8M; the latest was Early Stage VC ($12.9M) in Aug 2024.
- Notable investors include Oxford Science Enterprises, BioInnovation Institute, Syncona.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Kesmalea Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Kesmalea Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kesmalea Therapeutics
Developer of a pipeline of therapeutics designed to transform large protein degraders into small molecules for targeted protein degradation. The company's platform enables the creation of oral, CNS-penetrant degraders by inserting reversible linkers, allowing patients with chronic diseases such as oncology and CNS disorders to access innovative treatments.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 24
- Website
- kesmalea.com/
- Ownership
- Privately Held (backing)
Kesmalea Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kesmalea Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kesmalea Therapeutics in its N-PORT filings yet. We sweep new filings monthly.